You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Medtronic
Boehringer Ingelheim
Colorcon
Johnson and Johnson

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,555,029

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,555,029
Title:Methods of colchicine administration
Abstract: The invention provides improved methods for coadministration of colchicine with drugs metabolized by CYP3A4 (anciently referred to as cytochrome P450 isozyme 3A4) or the P-glycoprotein transporter, but not both. The method enables non-toxic coadministration of colchicine and the second drug at their ordinary levels safely and effectively without reducing the dose or frequency for either drug.
Inventor(s): Ducharme; Murray (St. Laurent, CA)
Assignee: HIKMA PHARMACEUTICALS LLC (JO)
Application Number:14/567,005
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,555,029
Patent Claims: 1. A method of treating a patient for an inflammatory disorder, wherein the inflammatory disorder is chronic gout, familial Mediterranean fever or Behcet's disease, with colchicine while concomitantly administering a second drug that is not an inhibitor of the cytochrome P450 3A4 isoenzyme (CYP3A4) but is an inhibitor of P-glycoprotein 1 (P-gp), wherein the second drug is propafenone, wherein the method comprises: a) administering to the patient a therapeutically effective fixed maintenance dose of colchicine in an amount of from about 0.6 to about 1.2 mg/day, for a maintenance period of a plurality of days, without administering propafenone; b) after step (a), administering to the patient one or more therapeutically effective doses of propafenone; and c) concomitantly with step (b), administering to the patient the fixed maintenance dose of colchicine of step (a) without dose reduction.

2. The method of claim 1, wherein propafenone is administered at a dose of from 300 mg/day to 900 mg/day.

3. The method of claim 1, wherein said fixed maintenance dose of colchicine is 0.6 mg/day.

4. The method of claim 1, wherein said fixed maintenance dose of colchicine is 1.2 mg/day.

5. The method of claim 1, wherein the inflammatory disorder is chronic gout.

6. The method of claim 1, wherein said plurality of days comprises at least 7 days.

7. The method of claim 1, wherein said fixed maintenance dose of colchicine is 0.6 mg/day, and said inflammatory disorder is chronic gout.

8. A method of treating a patient for an inflammatory disorder, wherein the inflammatory disorder is chronic gout, familial Mediterranean fever or Behcet's disease, by administering colchicine while concomitantly administering an inhibitor of P-glycoprotein 1 (P-gp) that is not an inhibitor of the cytochrome P450 3A4 isoenzyme (CYP3A4), wherein the inhibitor of P-gp--is propafenone, Wherein the method comprises: a) administering to the patient a therapeutically effective fixed maintenance dose of colchicine in an amount of from about 0.6 to about 1.2 mg/day, for a maintenance period of a plurality of days; without administering propafenone; b) after step (a), administering to the patient one or more therapeutically effective doses of propafenone; c) concomitantly with step (b), administering to the patient the fixed maintenance dose of colchicine of step (a) without dose reduction; and d) after step (c), discontinuing administration of propafenone and continuing to administer the fixed maintenance doses of colchicine administered in step (b) without dose adjustment.

9. The method of claim 8, wherein said fixed maintenance dose of colchicine is 0.6 mg/day, and said inflammatory disorder is chronic gout.

10. The method of claim 8, wherein said fixed maintenance dose of colchicine is 0.6 mg/day, said inflammatory disorder is chronic gout, and said propafenone is administered at a dose of from 300 mg/day to 900 mg/day.

11. The method of claim 8, wherein said fixed maintenance dose of colchicine is 1.2 mg/day, and said inflammatory disorder is chronic gout.

12. The method of claim 8, wherein said fixed maintenance dose of colchicine is 1.2 mg/day, said inflammatory disorder is chronic gout, and said propafenone is administered at a dose of from 300 mg/day to 900 mg/day.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Merck
Baxter
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.